127 results
424B3
PRTG
Portage Biotech Inc
6 Mar 24
Prospectus supplement
9:36pm
PORT - 7: Highly Selective and Potent A2B Adenosine Receptor Antagonist High potency and selectivity may provide important safety and efficacy advantages … , Renal Cell Cancer with high A2A expression PORT - 6 1a: MONOTHERAPY (Safety) Phase 1a Starting Dose (200 mg QD) (n=9 - 12) PORT - 7 100 mg 800 mg
6-K
EX-99.1
PRTG
Portage Biotech Inc
6 Mar 24
Current report (foreign)
9:11pm
Antagonist High potency and selectivity may provide important safety and efficacy advantages Activity in 4T1, CT26, and other disease models (asthma … : MONOTHERAPY (Safety) Phase 1a Starting Dose (200 mg QD) (n=9 - 12) PORT - 7 100 mg 800 mg Recommended P2 Dose Recommended P2 Dose PORT - 6 + PORT - 7 PORT
6-K
EX-99.1
PRTG
Portage Biotech Inc
28 Feb 24
Company focused on adenosine platform clinical development
6:42pm
(pembrolizumab), Merck’s anti-PD-1 therapy,” continued Dr. Walters.
Pipeline Updates
Following the Trial Safety Committee recommendation, the Company
424B3
PRTG
Portage Biotech Inc
28 Feb 24
Prospectus supplement
5:19pm
-601 clinical trial to evaluate the activity and safety of PORT-6 and PORT-7 alone and in combination. This trial will adapt over time and also include … safety cohorts for these two agents with other immune activating agents including others from our internal pipeline. Depending on the data, it can
6-K
EX-99.2
PRTG
Portage Biotech Inc
28 Feb 24
Current report (foreign)
5:17pm
of action on different tumors.
We have designed the ADPORT-601 clinical trial to evaluate the activity and safety of PORT-6 and PORT-7 alone … and in combination. This trial will adapt over time and also include safety cohorts for these two agents with other immune activating agents including others
424B3
mzxkoly2wm4a7ci
18 Jan 24
Prospectus supplement
5:41pm
6-K
EX-99.1
yf82dw5w 23v
18 Jan 24
Current report (foreign)
5:09pm
424B3
qor1yt lcb
4 Jan 24
Prospectus supplement
5:49pm
6-K
EX-99.1
fl5jd10c6 4kw
4 Jan 24
Current report (foreign)
8:10am
424B3
nc9m5k46
28 Nov 23
Prospectus supplement
4:03pm
6-K
EX-99.2
dsijn5eb ngejlz19oaq
28 Nov 23
Current report (foreign)
4:01pm
424B3
s17zdd7eoq at1uv
14 Nov 23
Prospectus supplement
6:00am
6-K
EX-99.1
rx6hcof1j13
13 Nov 23
Current report (foreign)
6:10am
6-K
EX-10.1
s5x5weg3
3 Oct 23
Current report (foreign)
4:05pm
424B5
efmsv5a
2 Oct 23
Prospectus supplement for primary offering
6:01pm
6-K
EX-99.1
z5iqfn
8 Sep 23
Current report (foreign)
4:01pm
6-K
EX-99.1
gvqw91d0vxyr6z j8uho
30 Aug 23
Current report (foreign)
8:00am
6-K
EX-99.2
qy0ntui 7gsz82
29 Aug 23
Current report (foreign)
4:01pm
6-K
EX-99.1
6ecynpr8bbu6jnpj8o5
14 Aug 23
Current report (foreign)
4:52pm
6-K
EX-99.1
je2fmj7 n68
31 Jul 23
Current report (foreign)
6:10pm